SB 688-FN - AS AMENDED BY THE SENATE
03/12/2020 1065s
2020 SESSION
20-2728
01/10
SENATE BILL 688-FN
AN ACT relative to the pricing of generic prescription drugs.
SPONSORS: Sen. Fuller Clark, Dist 21; Sen. Rosenwald, Dist 13; Sen. Hennessey, Dist 5; Sen. Sherman, Dist 24; Rep. McMahon, Rock. 7; Rep. Bartlett, Merr. 19
COMMITTEE: Commerce
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill clarifies the pricing of generic prescription drugs under the law governing consumer protection.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
03/12/2020 1065s 20-2728
01/10
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty
AN ACT relative to the pricing of generic prescription drugs.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Consumer Protection: Acts Unlawful. Amend RSA 358-A:2, XIV to read as follows:
XIV. Pricing of goods or services in a manner that tends to create or maintain a monopoly, or otherwise harm competition, including the pricing of generic prescription drugs.
2 Effective Date. This act shall take effect upon its passage.
20-2728
1/7/20
SB 688-FN- FISCAL NOTE
AS INTRODUCED
AN ACT prohibiting price gouging in the sale of prescription drugs.
FISCAL IMPACT: [ X ] State [ ] County [ ] Local [ ] None
|
| |||
| Estimated Increase / (Decrease) | |||
STATE: | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
Appropriation | $0 | $0 | $0 | $0 |
Revenue | $0 | $0 | $0 | $0 |
Expenditures | $0 | Indeterminable Increase | Indeterminable Increase | Indeterminable Increase |
Funding Source: | [ X ] General [ ] Education [ ] Highway [ ] Other |
The Judicial Branch was originally contacted for a fiscal note worksheet on November 18, 2019, which they have not provided as of January 7, 2020.
METHODOLOGY:
This bill requires the commissioner of the Department of Health and Human Services to notify the Department of Justice of certain price increases for essential off-patent or generic drugs. The bill authorizes the Department of Justice to issue a civil investigative demand upon receipt of notification of suspected price gouging or in any other case in which the Department has reasonable cause to believe that unfair price gouging has occurred or is about to occur. The Department of Justice expects the bill to result in an increased number of investigations, with an indeterminable fiscal impact. The Department of Health and Human Services likewise expects an indeterminable cost associated with monitoring and reporting on price increases.
AGENCIES CONTACTED:
Department of Health and Human Services, Department of Justice, and Judicial Branch
Date | Body | Type |
---|---|---|
Jan. 21, 2020 | Senate | Hearing |
March 12, 2020 | Senate | Floor Vote |
March 11, 2020 | Senate | Floor Vote |
: Died on Table
June 30, 2020: Introduced and Laid on Table MA VV 06/30/2020 HJ 10 P. 6
March 12, 2020: Ought to Pass with Amendment 2020-1065s, RC 24Y-0N, MA; OT3rdg; 03/12/2020; SJ 7
March 12, 2020: Sen. Feltes Moved to Reconsider the following action taken by this Body: Rescind Order to Third Reading and Final Passage, and Reconsider the Vote on Ought to Pass with Amendment, MA, VV; 03/12/2020; SJ 7
March 11, 2020: Ought to Pass with Amendment 2020-1065s, RC 14Y-10N, MA; OT3rdg; 03/11/2020; SJ 6
March 11, 2020: Committee Amendment # 2020-1065s, AA, VV; 03/11/2020; SJ 6
March 11, 2020: Committee Report: Ought to Pass with Amendment # 2020-1065s, 03/11/2020; SC 10
March 12, 2020: Committee Report: Ought to Pass with Amendment # 2020-1065s, 03/12/2020; SC 10
Jan. 21, 2020: Hearing: 01/21/2020, Room 100, SH, 01:15 pm; SC 3
Jan. 8, 2020: Introduced 01/08/2020 and Referred to Commerce; SJ 2